The agency is proposing to reduce the production amount of five opioids, including oxymorphone, fentanyl, hydrocodone, hydromorphone and oxycodone, which were subject to greater scrutiny after the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act was passed last year.
Combined with morphine, the proposal would lead to a 53 percent decrease in the allowable amount of these opioids since 2016, according to Drug Topics.
Read the full report here.
More articles on pharmacy:
Florida compounding facility recalls all human and animal drugs for lack of sterility
Despite ‘Right-to-try’ law, drugmakers still prefer FDA review, GAO finds
